Alnylam Pharmaceuticals (ALNY) Citi's Biopharma Back to School Conference summary

Product portfolio and market performance

• Six products are currently marketed, with four developed internally and a robust pipeline supporting long-term growth.

• Strong initial results from the ATTR cardiomyopathy launch in Q2 led to upgraded annual guidance.

• ATTR market is large but underpenetrated, with only about 20% of cardiomyopathy patients treated globally.

• Amvutra's uptake is balanced between first- and second-line use, with significant expansion in new prescribers.

• Revenue from polyneuropathy reached $1.2 billion last year, growing over 30% annually.

Competitive landscape and market dynamics

• ATTR market is not winner-take-all; multiple companies and products are expected to succeed.

• Early patient uptake for Amvutra was mostly second-line, but first-line use is increasing.

• Pfizer's withdrawal of Vyndaqel is seen as a commercial move, with most patients already on Vyndamax.

• Market growth is expected to accelerate as more therapies and companies drive diagnosis and treatment rates.

• Amvutra's orthogonal mechanism positions it well for second-line and combination therapy in the future.

Access, pricing, and payer considerations

• Achieved broad formulary access in major U.S. health systems in Q2, accelerating revenue uptake.

• Most payer policies now enable first-line use, but ongoing work is needed to maintain access.

• Net price for Amvutra in the U.S. is expected to gradually decrease due to rebating to maintain formulary position.

• Health systems hold minimal inventory; distribution is managed by a single distributor.